linjc16/ctgov huggingface dataset:
High Versus Standard Dose of Proton Pump Inhibitors (PPIs) in Peptic Ulcer Bleeding

Study Overview
=================
Brief Summary
-----------------
High intravenous dosage of Proton Pump Inhibitors is not better than standard dosage in bleeding peptic ulcers successfully treated by endoscopic therapy

Detailed Description
-----------------
The recent Canadian consensus conference on the management of patients with non-variceal upper gastrointestinal bleeding recommends a high regimen of PPIs, consisting in a dosage of 80-mg bolus followed by the 8 mg/H infusion, as being superior to the standard dosage (40 mg twice daily by bolus injection) in conjunction with some type of endoscopic therapy. However, by pooling data fromm studies comparing high doses of PPIs as continuous infusion versus regular doses as intermittent bolus, rebleeding, surgery, and mortality were not significantly different. As the previous conclusion became apparent in a meta-analytical evaluation of only 2 randomized clinical trials, more studies are needed on this topic.

Official Title
-----------------
Proton Pump Inhibitors in Conjunction to Endoscopic Therapy for Bleeding Peptic Ulcers: a Randomized Clinical Trial of High vs Standard Doses

Conditions
-----------------
Peptic Ulcers, Upper Gastrointestinal Bleeding

Intervention / Treatment
-----------------
* Drug: omeprazole
* Drug: pantoprazole


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Consecutive patients admitted for upper gastrointestinal bleeding secondary to peptic ulcers that have been successfully treated with endoscopic therapy Exclusion Criteria: Variceal esophageal bleeding Concurrent PPI use Moribund patients

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: omeprazole|nan|
|Drug: pantoprazole|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rebleeding rates and surgical needs |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PPIs,, endoscopic therapy,, peptic ulcers,, upper gastrointestinal bleeding,, non-variceal upper gastrointestinal bleeding
Efficacy of Serratus Anterior Plane Block Mastectomy

Study Overview
=================
Brief Summary
-----------------
Breast cancer is the main common cancer among females. . Inadequate control of pain may later develop into chronic pain syndrome (paraesthesias, phantom breast pain, and intercostobrachial neuralgia) in 25-40% of the patients .

Detailed Description
-----------------
The aim of this study is to compare the efficacy of ultrasound-guided serratus anterior plane block with bupivacaine/ magnesium versus bupivacaine/ nalbuphine in breast cancer surgery. Patients and methods nclusion criteria: -ASA I and II female patients, age 25-60 undergoing breast cancer surgery Exclusion criteria: Patient refusal Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy) Allergy to the drugs used in the study Chronic pain therapy, BMI more than 30 kg/m2

Official Title
-----------------
Efficacy of Serratus Anterior Plane Block Using Bupivacaine/Magnesium Sulphate Versus Bupivacaine/Nalbuphine for Mastectomy: a Randomized Double Blinded Comparative Study

Conditions
-----------------
Postoperative Pain, Postoperative Complications

Intervention / Treatment
-----------------
* Procedure: serratus anterior plan block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA I and II female patients, age 25-60 undergoing breast cancer surgery Exclusion Criteria: -Patient refusal Contraindications for regional blocks (eg. Infection at the injection site, coagulopathy) Allergy to the drugs used in the study Chronic pain therapy, BMI more than 30 kg/m2

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: GBM:( bupivacaine/magnesium sulphate)<br>serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia. GBM:( bupivacaine/magnesium sulphate): will receive bupivacaine 30 ml 0.25 and 500 mg magnesium sulphate | Procedure: serratus anterior plan block<br>* serratus anterior plan block<br>|
| Active Comparator: GBN: ( bupivacaine/nalpuphin)<br>serratus plane block will performed in the supine position under strict aseptic conditions before induction of anesthesia.. ( bupivacaine/nalpuphin):received bupivacaine 30 ml 0.25 % and nalpuphine 0.2mg/kg. | Procedure: serratus anterior plan block<br>* serratus anterior plan block<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to first analgesic requirements in minutes | time to first analgesic requirements in minutes by the patient | change from base line for 24 hours |
Rheumatologic Adverse Events and Cancer Immunotherapy

Study Overview
=================
Brief Summary
-----------------
In this study, every patient with cancer who is going to be treated by immunotherapy will fill in a form. In this form, we try to determine if he presents rheumatologic complications of his immunotherapy. If the patient answers yes to one question on the form, the patient will be see in rheumatologic consultation to explore his clinical signs. The number of patients referred in consultation thanks to this questionnaire will be compared to the number of patients who would have been spontaneously referred by the oncologist. The aim of this questionnaire is to optimise the management of rheumatological effects secondary to immunotherapy.

Official Title
-----------------
Rheumatologic Adverse Events and Immunotherapy in Oncology

Conditions
-----------------
Oncology, Autoimmunity, Arthritis, Adverse Drug Event

Intervention / Treatment
-----------------
* Other: Fill in a form


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient with cancer needed to be treated by immunotherapy Exclusion Criteria: Patient already treated by immunotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patient with cancer immunotherapy treatment<br>All patients starting immunotherapy treatment will complete a questionnaire to identify rheumatological side effects, each time they come for treatment. | Other: Fill in a form<br>* Patient will have to fill in a form at each perfusion of immunotherapy to tell if they presents rheumatologic clinical signs<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to determine whether a self-questionnaire completed by a patient treated with immunotherapy can identify more patients with rheumatological side effects related to this treatment, compared to the complaint reported by the patient to the oncologist | number of patients referred to a rheumatology consultation thanks to the answers to the questionnaire compared to the number of patients referred to a consultation (from questionnaire and oncologist) | ONE YEAR |
Cognitive Stimulation

Study Overview
=================
Brief Summary
-----------------
This research is being done to learn if computer tasks that challenge the brain (cognitively stimulating tasks) can improve memory and other types of thinking. The study will compare the effects of different versions of the computer tasks. It also will compare the task performance of different groups of people.

Official Title
-----------------
Effects of Cognitive Training in Methadone Maintenance Patients

Conditions
-----------------
Substance Use Disorders

Intervention / Treatment
-----------------
* Behavioral: Computerized cognitively stimulating activities


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age 18-55 in methadone maintenance or healthy volunteers healthy Exclusion Criteria: Axis I disorder (except substance abuse and dependence in methadone maintenance patients) severe cognitive impairment serious untreated medical condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Adaptive cognitively stimulating activities<br> | Behavioral: Computerized cognitively stimulating activities<br>* The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.<br>|
| Active Comparator: Non-adaptive cognitively stimulating activities<br> | Behavioral: Computerized cognitively stimulating activities<br>* The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Working Memory | Change in maximum number of digits correctly recalled in Digit Span Backwards task, from baseline to 7 weeks | baseline, 7 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Episodic Memory |  | baseline, 7 weeks | 
| Trail-making |  | baseline, 7 weeks | 
| go/No-go |  | baseline, 7 weeks | 
| Addiction Severity Index |  | baseline, 7 weeks | 
| Delay Discounting |  | baseline, 7 weeks | 
| Digit Symbol Substitution Test |  | baseline, 7 weeks |
Effect of FOV and mA on Metal Artifacts on CBCT

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the effect of exposure parameters as milliampere (mA) and field of view (FOV) in CBCT on metal artifact of dental implant.

Detailed Description
-----------------
Cone Beam Computed Tomography (CBCT) is considered an important valuable imaging technique in the diagnosis and treatment planning in oral and maxillofacial surgery as well as implant dentistry by means of three dimensional images which provide extra information about the buccolingual dimension of the alveolar bone with more details for bone anatomy and inclination. To make an accurate diagnosis and treatment planning, we have to obtain images with more details and good resolution and quality which could be achieved by CBCT. However, there are some issues in scanned areas that can affect their quality such as presence of metals (metallic restorations, orthodontic appliances, dental implants, crowns) which result in artifacts which can be considered as an important cause of poor image quality which will lead to poor diagnosis. There are many types of artifacts which can be observed on CBCT images. Beam hardening artifact is considered a common one which occurs when an x-ray beam comprised of polychromatic energies passes through an object, resulting in selective attenuation of lower energy photons. The effect is conceptually similar to a high-pass filter, in that only higher energy photons are left to contribute to the beam and thus the mean beam energy is increased (hardened).

Official Title
-----------------
Effect of Variations of Field of View (FOV) and Milliampere (mA) on Metal Artifacts Produced by Dental Implants in Cone Beam Computed Tomography Image Quality. (In-vitro Study)

Conditions
-----------------
Metal Artifacts, Implant

Intervention / Treatment
-----------------
* Radiation: CBCT radiation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Bio models of jaw with dummy implant. Exclusion Criteria: -
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Tube potential difference (FOV)<br>Using different FOV and mA values of the CBCT machine | Radiation: CBCT radiation<br>* CBCT scanning<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Dental implant linear measurement | The implant length and width in millimeters will be assessed in the presence of the artifacts with change in the potential difference of FOV and mA | 2 months |
Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start HAART: a Randomized Trial

Study Overview
=================
Brief Summary
-----------------
Highly active antiretroviral therapy (HAART) in HIV-positive patients is associated with the development of dyslipidemia, a risk factor for cardiovascular events. The objective of this study was to evaluate the effect of dietary intervention in individuals who start HAART.

Detailed Description
-----------------
Adult patients prescribed to HAART that met the exclusion criteria were consecutively enrolled in a randomized trial: control (receiving general guidelines on dietary education) intervention (receiving general guidelines on dietary education and nutritional follow-up every 3 months)

Official Title
-----------------
Effect of Nutritional Intervention on the Lipid Profile of HIV-Positive Patients Who Start on Highly Active Antiretroviral Therapy: a Randomized Trial

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Behavioral: Nutritional


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: HIV-positive individuals naive to HAART, with clinical indication to start therapy Exclusion Criteria: Diabetes Mellitus Pregnancy Active opportunistic disease Any mental deficiency Use of lipid profile influencing drugs Use of illicit drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Nutritional|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Total cholesterol and of triglycerides levels |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HDL-cholesterol, LDL-cholesterol, weight, waist to hip ratio |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HIV, HAART, Nutrition, Dyslipidemia
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population

Study Overview
=================
Brief Summary
-----------------
The primary objective of the RESOLUTE international registry is to document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a 'real-world' patient population requiring stent implantation.

Detailed Description
-----------------
As part of the broader clinical program of the Resolute stent, the RESOLUTE International registry will expand the experience and understanding of the device performance in a 'real-world' setting. The registry intends to enroll patients from a large number of centers under commercial usage conditions, with the aim to reflect 'real-world' usage as much as possible.

Official Title
-----------------
RESOLUTE International Registry: Evaluation of the Resolute Zotarolimus-Eluting Stent System in a 'Real-World' Patient Population

Conditions
-----------------
Coronary Artery Disease, Cardiovascular Diseases

Intervention / Treatment
-----------------
* Device: Endeavor Resolute Zotarolimus-Eluting Coronary Stent System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Minimum legal age (18) Acceptable candidate for treatment with a drug-eluting stent in accordance with applicable guidelines Patient has consented to participate and authorized in writing the collection and release of medical information Elective use of the Endeavor Resolute stent Exclusion Criteria: Pregnancy High probability of non-adherence to the follow-up requirements (due to social, psychological or medical reasons) Currently participating in another trial preventing routine hospital treatment Previous enrollment in the RESOLUTE International registry

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite Endpoint of Cardiac Death and Myocardial Infarction (Not Clearly Attributable to a Non-target Vessel) |  | 12 Months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Overall Stent Thrombosis, Defined as Definite and Probable Stent Thrombosis, According to the Academic Research Consortium (ARC) Definition |  | 12 Months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Drug Eluting Stent, Interventional Cardiology, Percutaneous Coronary Intervention
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

Study Overview
=================
Brief Summary
-----------------
Based on the literature, the pancreatic cancer treatment predictor biomarker, which is used in the domestic clinical field, is actually applied to the pancreatic cancer patient cohort of the National Cancer Center. To systematically prospectively identify prospective treatment response biomarkers for Pancreatic Cancer Cohort in the National Cancer Center

Detailed Description
-----------------
Immunohistochemistry and gene test for hENT1, DCK, SMAD4, CES2, BRCA 1/2,PALB2, MMRd, MSI, Tumor Ag and etc. on Cancer sample Collect data of Biomarker for pancreatic cancer Compare with Big data and Cohort study in National cancer center The number of subjects is changed by statistical consideration. 218->238

Official Title
-----------------
A Longitudinal, Observational Biomarker Study in Pancreatic Cancer Patients Receiving Chemotherapy

Conditions
-----------------
Pancreatic Cancer

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically Confirmed Pancreatic Cancer Patients Exclusion Criteria: Subjects who do not agree with the study
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| median survival | The length of time from either the date of diagnosis or the start of treatment for a disease,the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse | 5 years | 
| progressive-free survival | The length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse | 5 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pancreatic cancer, Biomarker, chemotherapy, pharmacogenomic, clinical trials